Lasa Supergenerics Limited (NSE:LASA)

India flag India · Delayed Price · Currency is INR
7.82
+0.08 (1.03%)
Mar 10, 2026, 11:49 AM IST
-67.23%
Market Cap 387.78M
Revenue (ttm) 669.61M
Net Income (ttm) -442.17M
Shares Out 50.10M
EPS (ttm) -9.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,305
Average Volume 40,727
Open 7.95
Previous Close 7.74
Day's Range 7.52 - 8.15
52-Week Range 7.18 - 24.83
Beta 0.05
RSI 41.04
Earnings Date Feb 13, 2026

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, s... [Read more]

Sector Healthcare
Founded 2016
Employees 66
Stock Exchange National Stock Exchange of India
Ticker Symbol LASA
Full Company Profile

Financial Performance

In fiscal year 2025, Lasa Supergenerics's revenue was 1.47 billion, an increase of 41.20% compared to the previous year's 1.04 billion. Losses were -147.57 million, -32.09% less than in 2024.

Financial Statements

News

There is no news available yet.